Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alg-1001
2. Risuteganib
1. Risuteganib
2. Alg-1001
3. Risuteganib [usan]
4. 1307293-62-4
5. Alg1001
6. 123dna66ia
7. Gly-arg-gly-cya-thr-pro
8. Risuteganib (usan)
9. Glycyl-l-arginylglycyl-3-sulfo-l-alanyl-l-threonyl-l-proline
10. L-proline, Glycyl-l-arginylglycyl-3-sulfo-l-alanyl-l-threonyl-
11. (2s)-1-[(2s,3r)-2-[[(2r)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic Acid
12. Risuteganib [inn]
13. Unii-123dna66ia
14. Alg-1001 Hexapeptide
15. Chembl4297529
16. Schembl19410626
17. Hy-p1930
18. Db14911
19. Cs-0019633
20. D11436
| Molecular Weight | 637.7 g/mol |
|---|---|
| Molecular Formula | C22H39N9O11S |
| XLogP3 | -8.1 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 17 |
| Exact Mass | 637.24897427 g/mol |
| Monoisotopic Mass | 637.24897427 g/mol |
| Topological Polar Surface Area | 347 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 1170 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Luminate® (risuteganib) is a novel anti-integrin peptide that targets the multiple integrin heterodimers involved in the pathophysiology of dry AMD, it is being investigated for the treatment of intermediate, non-exudative age-related macular degeneration.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 12, 2023
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Luminate® (risuteganib) is a novel anti-integrin peptide that targets the multiple integrin heterodimers involved in the pathophysiology of dry AMD, it is being investigated for the treatment of intermediate, non-exudative age-related macular degenerati...
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 12, 2023
Details:
Pre-clinical data suggest that Luminate (risuteganib), Allegro’s lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2023
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pre-clinical data suggest that Luminate (risuteganib), Allegro’s lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD.
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 10, 2023
Details:
These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2021
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 03, 2021
Details:
Bausch Health, has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro, including global rights for risuteganib (Luminate). Allegro include ALG-1007, a topical integrin regulator under investigation for treatment of dry eye disease.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Bausch Health
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2020
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : $50.0 million
Deal Type : Acquisition
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
Details : Bausch Health, has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro, including global rights for risuteganib (Luminate). Allegro include ALG-1007, a topical integrin regulator under investigation for treatmen...
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 21, 2020
Details:
The agreement provides Bausch with global rights for risuteganib, Allegro's lead investigational compound in retina, including Other ophthalmology assets such as Allegro's ALG-1007, a topical integrin regulator under investigation for the treatment of dry eye disease.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Bausch Health
Deal Size: $50.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition September 21, 2020
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : $50.0 million
Deal Type : Acquisition
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
Details : The agreement provides Bausch with global rights for risuteganib, Allegro's lead investigational compound in retina, including Other ophthalmology assets such as Allegro's ALG-1007, a topical integrin regulator under investigation for the treatment of dr...
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : $10.0 million
September 21, 2020
Details:
Risuteganib is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2018
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (...
Details : Risuteganib is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 13, 2018
Details:
Luminate (Risuteganib) is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Retinopathy.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Luminate
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Duke University | Trial Runners, LLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2015
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Duke University | Trial Runners, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PV...
Details : Luminate (Risuteganib) is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Retinopathy.
Product Name : Luminate
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 06, 2015
Details:
Luminate is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.
Lead Product(s): Risuteganib,Bevacizumab+Rituximab
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Trial Runners, LLC | Duke University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 28, 2015
Lead Product(s) : Risuteganib,Bevacizumab+Rituximab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Trial Runners, LLC | Duke University
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of D...
Details : Luminate is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 28, 2015
Details:
ALG-1001 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Symptomatic Focal Vitreomacular Adhesion.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2014
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALG-1001 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Symptomatic Focal Vitreomacular Adhesion.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 03, 2014
Details:
ALG-1001 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Lead Product(s): Risuteganib,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2012
Lead Product(s) : Risuteganib,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALG-1001 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 17, 2012
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
30
PharmaCompass offers a list of Risuteganib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Risuteganib manufacturer or Risuteganib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Risuteganib manufacturer or Risuteganib supplier.
A Risuteganib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Risuteganib, including repackagers and relabelers. The FDA regulates Risuteganib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Risuteganib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Risuteganib supplier is an individual or a company that provides Risuteganib active pharmaceutical ingredient (API) or Risuteganib finished formulations upon request. The Risuteganib suppliers may include Risuteganib API manufacturers, exporters, distributors and traders.
Risuteganib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Risuteganib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Risuteganib GMP manufacturer or Risuteganib GMP API supplier for your needs.
A Risuteganib CoA (Certificate of Analysis) is a formal document that attests to Risuteganib's compliance with Risuteganib specifications and serves as a tool for batch-level quality control.
Risuteganib CoA mostly includes findings from lab analyses of a specific batch. For each Risuteganib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Risuteganib may be tested according to a variety of international standards, such as European Pharmacopoeia (Risuteganib EP), Risuteganib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Risuteganib USP).
